No significant differences were observed among FTD subtypes, including GRN and C9orf72 mutant carriers, MAPT mutation carriers, or sporadic cases, indicating that Cathepsin S is not a reliable biomarker for differentiating clinical, genetic, or pathological groupings (56). The gene discussed is MAPT; the disease is frontotemporal dementia.